Tag: Eli Lilly and Company

Clinical Trials Healthcare & Pharmaceuticals News

Lilly’s Retevmo Shows Substantial Survival Benefit in Early-Stage Lung Cancer Trial

Eli Lilly and Company

Eli Lilly’s Retevmo (selpercatinib) has shown promising results as an adjuvant therapy for early-stage lung cancer. The Phase 3 LIBRETTO-432 trial revealed that Retevmo adjuvant therapy significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer (NSCLC), marking a breakthrough for this rare molecular subtype affecting 1-2% of lung cancer cases.

Business News Oncology

Lilly to Acquire Orna Therapeutics in $2.4 Billion Deal to Revolutionize In Vivo Cell Therapy

Eli Lilly and Company

Eli Lilly has entered a $2.4 billion definitive agreement to acquire Orna Therapeutics. This strategic move integrates Orna’s proprietary circular RNA platform and in vivo CAR-T pipeline into Lilly’s growing portfolio, signaling a major shift toward more accessible and scalable genetic medicines for B cell-driven autoimmune diseases.

Business Anti-obesity Drugs Diabetes News

Eli Lilly Released Q4 and 2025 Results; Projects $80B+ Revenue for 2026 as Oral Weight-Loss Drug Orforglipron Nears Approval

Eli Lilly and Company

Eli Lilly (LLY) shattered Q4 2025 expectations with $19.3 billion in revenue, marking a 43% year-over-year increase. Driven by the explosive demand for weight-loss treatments Mounjaro and Zepbound, the pharmaceutical giant issued a confident 2026 revenue guidance of $80B–$83B, signaling continued dominance in the metabolic health market.

Business Manufacturing News

Lilly Unveils Historic $3.5 Billion Manufacturing Investment in Pennsylvania for Next-Gen Weight-Loss Medicines

Eli Lilly and Company

Eli Lilly and Company has announced a historic $3.5 billion investment to establish a state-of-the-art manufacturing campus in Fogelsville, Pennsylvania. As the largest life sciences project in the Commonwealth’s history, this facility will be dedicated to producing next-generation injectable medicines, including the investigational triple hormone receptor agonist retatrutide. The project is set to create 850 high-value jobs and solidify the Lehigh Valley as a premier global hub for pharmaceutical innovation and domestic supply chain resilience.

Clinical Trials Healthcare & Pharmaceuticals News

Lilly’s Triple-Agonist Retatrutide Delivers Unprecedented Weight Loss, Dramatically Reduces Osteoarthritis Pain in Phase 3 Trial

Eli Lilly and Company

Eli Lilly and Company announced groundbreaking positive topline results from the Phase 3 TRIUMPH-4 clinical trial, confirming its investigational triple-agonist drug, retatrutide, delivered unprecedented weight loss of up to 28.7% (71.2 lbs) and substantial relief from the pain and functional limitations associated with knee osteoarthritis.

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Lilly’s Jaypirca Outperforms Imbruvica in Landmark Phase 3 Trial for CLL/SLL

Eli Lilly and Company

Eli Lilly announced that its non-covalent BTK inhibitor, Jaypirca (pirtobrutinib), met the primary endpoint of non-inferiority on Overall Response Rate (ORR) when compared to Imbruvica (ibrutinib) in the landmark BRUIN CLL-314 Phase 3 trial. The drug demonstrated numerically higher efficacy (87.0% ORR) and a significant safety advantage, including much lower rates of atrial fibrillation/flutter and hypertension, positioning Jaypirca as a potential new front-line therapy for CLL/SLL.

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

U.S. FDA Grants Full Approval to Lilly’s Jaypirca® for Expanded Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Eli Lilly and Company

U.S. FDA has granted full approval to Eli Lilly’s Jaypirca (pirtobrutinib) for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This expanded indication allows the use of the non-covalent BTK inhibitor immediately following prior covalent BTK inhibitor therapy. The decision is bolstered by data from the Phase 3 BRUIN CLL-321 trial, which demonstrated a statistically significant improvement in progression-free survival compared to standard combinatorial therapies.

Healthcare & Pharmaceuticals Anti-obesity Drugs Business News Weight-loss Drugs

Eli Lilly Cuts Zepbound Prices for Self-Pay Patients Following White House Deal

Eli Lilly and Company

In a major move to improve affordability and counter the compounded drug market, Eli Lilly has cut the monthly cost of Zepbound to $299 for the starter dose. Available exclusively through LillyDirect, these new single-dose vials offer a significant discount for patients without insurance coverage. Read the full details on the new pricing structure and how it impacts the weight-loss drug market.

Clinical Trials Healthcare & Pharmaceuticals News

Eli Lilly’s Eloralintide Shows Up to 20.1% Weight Loss in Phase 2 Obesity Study

Eli Lilly and Company

Eli Lilly and Company announced positive Phase 2 trial results for eloralintide, its investigational once-weekly, selective amylin receptor agonist. The study met its primary endpoint, showing that adults with obesity or overweight achieved mean weight reductions of up to 20.1% over 48 weeks, compared to 0.4% with placebo. The drug also demonstrated a favorable tolerability profile, with mild-to-moderate gastrointestinal symptoms being the most common adverse events. Lilly plans to advance eloralintide to Phase 3 trials by the end of 2025.